MX2022006069A - Metodo para tratar glomerulopatia c3. - Google Patents

Metodo para tratar glomerulopatia c3.

Info

Publication number
MX2022006069A
MX2022006069A MX2022006069A MX2022006069A MX2022006069A MX 2022006069 A MX2022006069 A MX 2022006069A MX 2022006069 A MX2022006069 A MX 2022006069A MX 2022006069 A MX2022006069 A MX 2022006069A MX 2022006069 A MX2022006069 A MX 2022006069A
Authority
MX
Mexico
Prior art keywords
glomerulopathy
treating
human
susceptible
administering
Prior art date
Application number
MX2022006069A
Other languages
English (en)
Inventor
Petrus Bekker
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2022006069A publication Critical patent/MX2022006069A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Abstract

Se proporcionan métodos para tratar un humano que padece de o es susceptible a glomerulopatía C3 que comprende administrar al humano una cantidad efectiva de un antagonista de C5aR.
MX2022006069A 2016-01-14 2017-01-12 Metodo para tratar glomerulopatia c3. MX2022006069A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662278788P 2016-01-14 2016-01-14
US201662280346P 2016-01-19 2016-01-19
US201662347450P 2016-06-08 2016-06-08
US201662397527P 2016-09-21 2016-09-21
PCT/US2017/013132 WO2017123716A1 (en) 2016-01-14 2017-01-12 Method of treating c3 glomerulopathy

Publications (1)

Publication Number Publication Date
MX2022006069A true MX2022006069A (es) 2023-01-12

Family

ID=59312069

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022006069A MX2022006069A (es) 2016-01-14 2017-01-12 Metodo para tratar glomerulopatia c3.
MX2018008624A MX2018008624A (es) 2016-01-14 2017-01-12 Metodo para tratar glomerulopatia c3.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018008624A MX2018008624A (es) 2016-01-14 2017-01-12 Metodo para tratar glomerulopatia c3.

Country Status (17)

Country Link
US (3) US20170202821A1 (es)
EP (1) EP3402486A4 (es)
JP (3) JP7339733B2 (es)
KR (1) KR20180102642A (es)
CN (1) CN108601790A (es)
AU (1) AU2017207359C1 (es)
BR (2) BR122024002810A2 (es)
CA (1) CA3010735C (es)
IL (1) IL260539B (es)
MA (1) MA43872A (es)
MX (2) MX2022006069A (es)
NZ (1) NZ744083A (es)
RU (1) RU2742888C2 (es)
SG (1) SG11201805828YA (es)
TW (1) TWI791423B (es)
WO (1) WO2017123716A1 (es)
ZA (1) ZA201804513B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172338A1 (en) 2008-12-22 2011-07-28 Chemocentryx Inc C5ar antagonists
US9126939B2 (en) 2010-06-24 2015-09-08 Pingchen Fan C5AR antagonists
MA52308A (fr) 2014-09-29 2021-02-24 Chemocentryx Inc Procédés et intermédiaires pour la préparation d'antagonistes c5ar
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
MX2022006069A (es) 2016-01-14 2023-01-12 Chemocentryx Inc Metodo para tratar glomerulopatia c3.
EP3589628A4 (en) 2017-03-01 2021-03-31 Achillion Pharmaceuticals, Inc. ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISEASES
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3658657A1 (en) * 2017-07-27 2020-06-03 Procter & Gamble International Operations SA. Phase-stable, sprayable freshening compositions comprising suspended particles
JP2021525860A (ja) * 2018-05-25 2021-09-27 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体代替経路関連腎症バイオマーカー
BR112021004263A2 (pt) 2018-09-06 2021-05-25 Achillion Pharmaceuticals, Inc. formas mórficas de danicopano
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
MX2021003425A (es) 2018-09-25 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
IL283450B1 (en) 2018-11-30 2024-02-01 Chemocentryx Inc Solid solution capsule formulations containing (3S,2R)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl) Piperidine-3-carboxamide, methods for their preparation and their medical uses
MX2023001504A (es) * 2020-08-07 2023-04-27 Kira Pharmaceuticals Suzhou Ltd Compuestos como inhibidores del receptor del componente complemento 5a (c5ar).
CN116635075A (zh) * 2020-12-21 2023-08-22 坎莫森特里克斯公司 使用c5a抑制剂治疗c3肾小球病
CN115192563B (zh) * 2022-05-09 2023-10-13 北京大学第一医院 C3a/C3aR通路拮抗剂治疗原发性膜性肾病的用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
CN1261098C (zh) 1998-08-28 2006-06-28 西奥斯股份有限公司 p38－α激酶的抑制剂
RU2197288C2 (ru) * 1999-08-03 2003-01-27 Тверская медицинская академия Способ лечения больных хроническим гломерулонефритом
AU2001259511A1 (en) 2000-05-05 2001-11-20 Smith Kline Beecham Corporation Novel anti-infectives
ES2353077T3 (es) 2000-08-10 2011-02-25 Mitsubishi Tanabe Pharma Corporation Derivados de urea con sustitución en posición 3 y uso medicinal de los mismos.
US7855297B2 (en) 2000-09-14 2010-12-21 Mitsubishi Tanabe Pharma Corporation Amide derivatives and medicinal use thereof
YU23503A (sh) 2000-09-29 2006-03-03 Neurogen Corporation Mali molekuli kao modulatori receptora c5a visokog afiniteta
CN100391537C (zh) 2001-08-17 2008-06-04 建南德克公司 结合至c5和c5a但不阻止c5b形成的补体途径抑制剂
TWI265164B (en) 2001-09-21 2006-11-01 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
CA2479930A1 (en) 2002-03-28 2003-10-09 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
AU2003225971A1 (en) 2002-03-28 2003-10-13 Yang Gao Substituted biaryl amides as c5a receptor modulators
AU2003220553A1 (en) 2002-03-29 2003-10-20 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
WO2004014905A1 (en) 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
US7169775B2 (en) 2002-08-21 2007-01-30 Neurogen Corporation Amino methyl imidazoles as C5a receptor modulators
FR2846654A1 (fr) 2002-11-05 2004-05-07 Servier Lab Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7455837B2 (en) 2002-11-05 2008-11-25 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
CA2504941C (en) 2002-11-08 2012-06-26 Neurogen Corporation 3-substituted-6-aryl pyridines
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
CA2528652A1 (en) 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
US20060154917A1 (en) 2003-07-03 2006-07-13 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
NZ551603A (en) 2004-06-24 2010-11-26 Incyte Corp N-substituted piperidines and their use as pharmaceuticals
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
NZ561613A (en) 2005-02-18 2010-12-24 Astrazeneca Ab Antibacterial piperidine derivatives
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
JP5374157B2 (ja) 2005-11-24 2013-12-25 ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ （ｒ）−アリールアルキルアミノ誘導体類と、それらを含有する薬剤組成物
EP4316465A3 (en) 2006-03-15 2024-04-24 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
WO2008022060A2 (en) 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
US8198266B2 (en) * 2006-10-31 2012-06-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of an EGFR antagonist for the treatment of glomerolonephritis
WO2009004650A1 (en) 2007-06-29 2009-01-08 Torrent Pharmaceuticals Ltd. Novel substituted piperidones as hsp inducers
WO2010019210A2 (en) 2008-08-11 2010-02-18 President And Fellows Of Harvard College Halofuginone analogs for inhibition of trna synthetases and uses thereof
US20110172126A1 (en) 2008-09-03 2011-07-14 Xenome Ltd Libraries of peptide conjugates and methods for making them
US20100074863A1 (en) 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
EP2894165B1 (en) * 2008-11-10 2023-01-04 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
SG172338A1 (en) 2008-12-22 2011-07-28 Chemocentryx Inc C5ar antagonists
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
US20120252792A1 (en) 2009-09-17 2012-10-04 The Regents Of The University Of Michigan Methods and compositions for modulating rho-mediated gene transcription
US9126939B2 (en) 2010-06-24 2015-09-08 Pingchen Fan C5AR antagonists
US8147400B1 (en) * 2011-01-17 2012-04-03 Coloplast A/S Penile implant with dilatant liquid
BR112014031375A2 (pt) * 2012-06-20 2017-06-27 Novartis Ag moduladores da série de reação complementar e usos dos mesmos
CN105392803B (zh) 2013-05-08 2019-12-06 诺和诺德股份有限公司 C5aR拮抗剂的用途
MA52308A (fr) 2014-09-29 2021-02-24 Chemocentryx Inc Procédés et intermédiaires pour la préparation d'antagonistes c5ar
MX2022006069A (es) 2016-01-14 2023-01-12 Chemocentryx Inc Metodo para tratar glomerulopatia c3.
CA3019137A1 (en) 2016-04-04 2017-10-12 Chemocentryx, Inc. Soluble c5ar antagonists
CN116635075A (zh) 2020-12-21 2023-08-22 坎莫森特里克斯公司 使用c5a抑制剂治疗c3肾小球病

Also Published As

Publication number Publication date
BR112018014222A2 (pt) 2018-12-11
BR122024002810A2 (pt) 2024-03-12
EP3402486A4 (en) 2019-08-28
US11285138B2 (en) 2022-03-29
US20170202821A1 (en) 2017-07-20
ZA201804513B (en) 2024-01-31
RU2018129378A3 (es) 2020-05-20
TWI791423B (zh) 2023-02-11
JP2021183625A (ja) 2021-12-02
JP2019501935A (ja) 2019-01-24
EP3402486A1 (en) 2018-11-21
RU2018129378A (ru) 2020-02-14
TW201726134A (zh) 2017-08-01
AU2017207359A1 (en) 2018-07-26
JP7339733B2 (ja) 2023-09-06
SG11201805828YA (en) 2018-08-30
US11779576B2 (en) 2023-10-10
MX2018008624A (es) 2018-12-10
NZ744083A (en) 2022-07-01
RU2742888C2 (ru) 2021-02-11
AU2017207359C1 (en) 2022-09-01
CA3010735C (en) 2023-06-13
US20220354837A1 (en) 2022-11-10
MA43872A (fr) 2021-05-19
CA3010735A1 (en) 2017-07-20
US20190201388A1 (en) 2019-07-04
CN108601790A (zh) 2018-09-28
JP2023126235A (ja) 2023-09-07
WO2017123716A1 (en) 2017-07-20
KR20180102642A (ko) 2018-09-17
AU2017207359B2 (en) 2022-04-14
IL260539B (en) 2021-05-31

Similar Documents

Publication Publication Date Title
ZA201804513B (en) Method of treating c3 glomerulopathy
MX2018004947A (es) Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados.
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
IL273959A (en) Methods and preparations for the treatment of rare diseases
WO2016044189A8 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
MX2017010150A (es) Bacterias probioticas recombinantes.
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
HK1254432A1 (zh) 用於治療纖維性疾病的方法和組合物
MX2015012428A (es) Tratamiento contra enfermedades mediadas th2 por inhibicion de bromodominios.
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
IL267253A (en) Methods for treating cochlear synaptopathy
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2017000306A (es) Metodos para tratar hipotension.
NZ722600A (en) Methods of treating mild brain injury
WO2016094899A3 (en) Treatment of hmgb1-mediated inflammation
IL283069A (en) Methods of administering corticosteroids
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2018001684A (es) Metodo de curacion de heridas.
MX2023003924A (es) Metodos de administracion de tratamiento antifibrotico.
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.